Who is sponsoring NCT01296815?

NCT01296815 is sponsored by Centro de Investigación en. Enfermedades Infecciosas, Mexico.

What condition does NCT01296815 study?

NCT01296815 studies Kaposi´s Sarcoma.

What is the status of NCT01296815?

NCT01296815 is currently COMPLETED.

Last reviewed 2015-07-22 · How we verify

Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity

NCT01296815 Phase 2 COMPLETED Results posted

Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed. The purpose of this study is to compare the effectiveness of intralesional bevacizumab + HAART vs HAART alone in treating localized Kaposi´s sarcoma of the airway in patients with AIDS.

Details

Lead sponsor	Centro de Investigación en. Enfermedades Infecciosas, Mexico
Phase	Phase 2
Status	COMPLETED
Enrolment	14
Start date	2010-09
Completion	2013-12

Conditions

Kaposi´s Sarcoma

Interventions

Bevacizumab

Primary outcomes

Number of Participants With Complete Response — 12 months
Complete response will be assessed according to RECIST criteria

Countries

Mexico